shutterstock_292920209

UCB and Biogen’s lupus drug falls short at Phase 2b

pharmafile | October 24, 2018 | News story | Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure 

The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet its primary endpoint in the treatment of moderately-to-severely active systemic lupus erythematosus (SLE) in adult patients during a Phase 2b trial.

The anti-CD40L pegylated fab was tested in 182 patients with the condition who had not seen results despite receiving standard-of-care treatments like corticosteroids, non-biological immunosuppressants and non-malarials, in groups randomised to receive it in combination with these treatments at one of three doses. However, it failed to demonstrate a dose response after 24 weeks, according to the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA).

Despite this, the pair did note that top-line results demonstrated that the therapy produced “consistent and potentially meaningful improvements for the majority of clinical endpoints” compared with placebo, and that biomarker data showed evidence of proof of biology.

“Biogen and UCB continue to further evaluate these data while assessing potential next steps. The companies expect to present this data at a future scientific forum,” the pair concluded.

Advertisement

Matt Fellows

Related Content

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder

UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis

UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …

The Gateway to Local Adoption Series

Latest content